Form 4: Dianthus Therapeutics Director Sujay Kango Acquires 25,000 Stock Options
SEC Form 4 Filing
Director Sujay Kango of Dianthus Therapeutics acquired 25,000 stock options on March 4, 2025, according to a Form 4 filing with the SEC.
Summary
- Sujay Kango, a director of Dianthus Therapeutics, acquired 25,000 stock options on March 4, 2025.
- The exercise price of these options is $19.86.
- The options vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service to the issuer.
- The options expire on March 4, 2035.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, neither particularly positive nor negative. It simply reports a transaction.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction: acquisition of stock options. |
| 03/04/2025 | Grant date of the stock options. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
| 03/04/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.